TUBERCULOSIS (TB) is one of the oldest infectious diseases known to man, and mostly affects groups of lower socio-economic status. 1 It is the second leading cause of mortality due to an infectious disease globally. 2 According to the World Health Organization, 8.8 million people were infected with TB in 2010, leading to 1.4 million deaths worldwide. 2 Iran has a high prevalence of TB, with an annual cumulative incidence of 13 cases per 100 000 population. 3 The increasing global burden of TB is linked to adverse drug reactions, particularly drug-induced hepatotoxicity, drug resistance and human immunodefi ciency virus (HIV) infection. 1, 4 Therapeutic drug monitoring (TDM) is an accepted clinical tool used in the management of many infectious diseases. TDM allows clinicians to make timely adjustments to drug regimens for patients who fail to respond to anti-tuberculosis drugs, such as slow responders and predisposed patients with drug interactions, as well as for early detection of therapeutic failure. 5, 6 Low anti-tuberculosis drug concentrations are common, and are associated with relapse, treatment failure and resistance, resulting in poor clinical outcomes. 7 The measurement of plasma concentrations of anti-tuberculosis drugs and the establishment of a correlation between drug concentrations and likely contributing factors are therefore essential, 8, 9 although it should be kept in mind that drug concentrations are only one of many factors affecting anti-tuberculosis treatment. 5 Anti-tuberculosis drug plasma concentrations have been observed to be related to factors such as age, sex, albumin, HIV infection, smoking status and alcohol consumption. [10] [11] [12] The aim of the present study was to determine plasma concentrations of the fi rst-line anti-tuberculosis drugs isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA) simultaneously in pulmonary TB patients. The analytical method was developed using a 
M E T H O D S :
The study was performed among 60 pulmonary tuberculosis (TB) in-patients at a tertiary care university-affiliated hospital in Tehran, Iran. Drug samples were drawn 2 and 6 h post dose for isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA); related concentrations were determined using high-performance liquid chromatography. Plasma drug concentrations, duration of treatment, age, sex, liver enzyme levels, administered doses and smoking status were evaluated and recorded.
R E S U LT S :
Among 60 patients recruited to the study, the mean (±SD) age was 54.2 (±20.9) years; 39 were female. The median peak plasma concentrations (C max ) of INH, RMP and PZA were respectively 2.5, 4.0 and 43.6 μg / ml; 81% of the patients had drug plasma concentrations lower than the target ranges for at least one administered drug. Respectively 49.1%, 92.5% and 8.7% of the patients had low concentrations of INH, RMP and PZA.
C O N C L U S I O N :
The results indicate that RMP concentrations are below the reference range in most patients, while PZA is within the target range of the standard doses. K E Y W O R D S : plasma concentrations; therapeutic drug monitoring high performance liquid chromatography (HPLC) system equipped with an ultraviolet (UV) detector. As ethambutol (EMB) does not have a chromophore group, it is not detectable by a UV detector; EMB concentrations were therefore not determined in our study. 13 Moreover, EMB has less therapeutic value than other fi rst-line anti-tuberculosis drugs and is rarely responsible for serious adverse effects, such as hepatotoxicity, frequently associated with the other anti-tuberculosis drugs. 14 Few data are available on plasma concentrations of anti-tuberculosis drugs in patients in Iran or other countries in the region.
STUDY POPULATION AND METHODS

Study population and definitions
The present observational study was performed at the Masih Daneshvari Hospital, National Research Institute of Tuberculosis and Lung Diseases, Tehran, Iran, from May 2009 to June 2011 following approval by the hospital's Ethics Committee. Patients aged >14 years admitted to the hospital with a diagnosis of pulmonary TB were enrolled in the study after providing written informed consent.
Study subjects were administered the conventional daily 2-month intensive phase of the four-drug antituberculosis regimen, consisting of 250-300 mg INH (Darou Pakhsh Pharmaceutical Co, Tehran, Iran), 450-600 mg RMP (Alhavi Pharmaceutical Co, Tehran, Iran), 1000 mg PZA (Laboratoires Sterop, Brussels, Belgium) and 400 mg EMB (Iran Darou Co, Tehran, Iran). All drugs were approved by the Iran Ministry of Health and their bioequivalence was confi rmed by the manufacturer. All drugs were taken on an empty stomach. Blood samples were drawn once patients had been on treatment for 7 days. Hospital staff observed daily ingestion of anti-tuberculosis drugs.
Patients with any of the following conditions were excluded from the study: HIV infection, heavy smoking (more than one pack per day), chronic alcohol consumption, pregnancy, known drug resistance, diabetes mellitus, end stage renal or hepatic disease and cystic fi brosis, and patients receiving drugs known to interact with INH, RMP and PZA, such as antifungal azoles, macrolids that may increase the concentration of RMP, antacids, and corticosteroids, which can reduce INH values.
The demographic data of eligible patients were extracted from the patient charts (Table) . Variables studied included age, sex, weight, smoking status, daily dose of each drug studied, drug-induced hepatitis, baseline liver function tests and 2 and 6 h post-dose drug concentrations. Reference ranges for INH, RMP and PZA were respectively 3-5, 8-24 and 20-50 μg / ml. 5, 15 These ranges represent the expected (average) concentrations in adults with standard doses of antituberculosis drugs. 5 
Drug-induced liver injury
Drug-induced liver injury is considered when alanine aminotransferase levels are three times higher than the upper limit of normal (ULN) in the presence of hepatitis symptoms or elevation of up to fi ve times the ULN in the absence of symptoms. 16 Sample preparation and calibration curves Blood samples were taken 2 and 6 h after drug administration. Separated plasma was centrifuged and immediately frozen at −70°C. Samples were then prepared for injection into the HPLC system using nicotinamide as internal standard (10 μg /ml). Acetonitrile, zinc sulphate and ammonia were used to precipitate the plasma proteins. Samples were vigorously mixed using a vortex shaker after each addition. The chromatographic equipment consisted of an Agilent HPLC 1200 series pump (Agilent Technologies, Santa Clara, CA, USA); a UV detector adjusted at two set wavelengths: 254 to detect INH and PZA, and 336 nm to detect RMP; a C18 reversed-phase column (250.0 × 4.6 mm, 5 μm); and a micro autosampler. The volume of injection of the clear supernatant was 100 μl, and chromatographic separation was performed at room temperature for 28 min. The mobile phase was a gradient of water and methanol. The method was designed to simultaneously detect fi rst-line antituberculosis drug plasma concentrations (INH, RMP and PZA) in one HPLC runtime. Calibration curves were constructed using spiked plasma samples over the concentration ranges of respectively 0.5-20, 1-40 and 1.5-60 μg /ml for INH, RMP and PZA. Finally, concentrations of unknown samples were calculated by interpolation on the calibration curves.
To confi rm the applicability of this method, the linearity of the calibration curves, precision, accuracy and limits of quantifi cation and detection were determined for the analysis of INH, RMP and PZA. The linearity of the calibration plot was in the following ranges: 0.5-20 μg /ml for INH, 1.5-60 μg /ml for PZA and 1.0-40 μg /ml for RMP. Intra-day precision was 2.6-4% for INH, 5.2-8% for PZA and 2.1-9.3% for RMP. Inter-day precision was 3.5-4% for INH, 2.7-11.5% for PZA and 3.6-8.9% for RMP. The ranges of accuracy of the method were 92.5-106.5% for INH, 96-99% for PZA and 92-105% for RMP. The limits of quantifi cation were respectively 0.5, 1.5 and 1.0 μg /ml for INH, PZA and RMP. The limits of detection were calculated as one third of the limits of quantifi cation. All calibration standards were prepared using the procedure mentioned above; the integrated peak areas were used to draw calibration curves.
Statistical analysis
To explore the associations between the drug concentrations and the study variables, data analyses were performed using the following statistical tests: Spearman's rank correlation and Kendall's rank correlation for ratio variables with a non-normal distribution of residuals; Student's t-test for normally distributed variables; the Mann-Whitney U-test for non-normally distributed variables; the χ 2 test for categorical parameters; and the multivariate ridge regression for fi nal model building of variables correlated to anti-tuberculosis drug concentrations. P < 0.05 was considered signifi cant. PASW Statistics version 18.0 (SPSS Inc, Chicago, IL, USA) was used for data analysis.
A three-stage data analysis was developed in which any relationship between the study variables and the anti-tuberculosis drug concentrations was assessed using univariate analyses. In the second stage, signifi cant interactions between the variables (obtained from the fi rst-stage analyses) that were associated with plasma levels of anti-tuberculosis drugs with P < 0.05, were evaluated. At the third stage of the data analysis, a multivariate ridge regression analysis was performed instead of the ordinary multivariate regression analysis, as statistically signifi cant interactions were observed between the study variables in the second stage. These variables were highly likely correlated with the plasma concentrations of the anti-tuberculosis drugs.
RESULTS
A total of 60 TB patients (mean [± standard deviation] age 54.2 [±20.9] years; 39 females; mean weight 53.6 [±10.9] kg) who met the study criteria were enrolled in the study (Table) . All samples were taken at least 7 days after starting treatment. One hundred and sixty samples collected from another group of 80 patients were discarded due to inappropriate storage at −20°C and sample collection was repeated and frozen at −70°C.
Three patients suffered from drug-induced hepatitis. In two of these, the plasma concentrations of the three study drugs were higher than the mean plasma concentrations overall. The highest value of the 2-h and 6-h concentrations is considered the peak plasma concentration (C max ), which was similar to 2-h values in our study. The median C max of INH, RMP and PZA was respectively 2.5, 4.0 and 43.6 μg /ml.
The assessment of the plasma concentrations of anti-tuberculosis drugs generated the following results: 81% of the patients had drug plasma concentrations lower than the target ranges for at least one administered drug. Concentrations were lower than expected for at least two drugs in 48% of the patients. In 12% of the study population, the plasma concentrations of all three administered drugs were lower than target ranges.
The following low drug concentrations were observed: INH (28/57, 49.1%); RMP (50/54, 92.5%) and PZA (5/57, 8.7%); 34% of the patients had low concentrations of both INH and RMP. There was no signifi cant relationship between plasma concentrations and the factors studied, apart from an apparent difference in 2-h INH plasma concentration between female and male patients, as well as a trend towards a lower 6-h INH plasma concentration in males than in females. The median 2-h INH plasma concentrations were respectively 3.2 (interquartile range [IQR] 1.9-5.0) and 1.9 (IQR 1.2-2.5) μg /ml in females and males (P = 0.003). The median 6-h INH plasma concentrations were respectively 1.6 (IQR 1.1-2.3) and 1.0 (IQR 0.6-1.6) μg /ml in females and males (P = 0.06).
DISCUSSION
In the present study, we observed low concentrations of anti-tuberculosis drugs in a signifi cant number of patients (respectively 49%, 92% and 8% for INH, RMP and PZA). RMP induces its own metabolism over the fi rst few weeks of treatment, 17 and our results would include this auto-induction effect. By delaying TDM after the completion of auto-induction, more patients with low drug concentrations would be expected. 17 In one study, patients who were identifi ed as slow responders had low RMP and INH concentrations. 15 TDM, followed by the correction of lower than expected ranges, could therefore aid in avoiding drug resistance as well as unnecessary costs. In the case of PZA, the majority of our patients had concentrations within the target range, which is perhaps due to the wide reference range for PZA (20-50 μg /ml).
The prevalence of low drug plasma concentration is common and has been studied previously. 10, 18, 19 In Tappero et al., 30% of patients had low serum concentrations of INH and 26% had low concentrations of both INH and RMP. 18 Low values for both INH and RMP, the two most effective anti-tuberculosis drugs, were also identifi ed in 34% of our patients. Although the prevalence of low drug plasma concentrations may show wide variations for a particular drug in TB patients, 7, 10 other studies have reported that low drug concentrations were associated with factors such as patient age, sex, drug dosage, malabsorption, low albumin and patient acetylator profi le. 4, 7 In most cases, low drug concentrations can be corrected by dose adjustment; 20 however, the relation between low plasma concentrations and clinical outcome is not well defi ned and requires extensive pharmacokinetic studies. 7 According to previous studies, low concentrations of INH range from 2% to 48% and plasma concentrations are related to factors such as age, sex, history of TB, HIV infection and fi xed-drug combination formulations. 20 In a previous clinical study on INH blood concentrations, we observed low concentrations of the drug in 14.6% of patients and reported a significant correlation between INH plasma concentrations and duration of INH administration (P < 0.001), i.e., INH concentration increased with each day of treatment. 21 In the present study, low INH concentrations were found in almost half of our patients. Furthermore, the median INH serum concentration was higher in female patients than in males at 2 and 6 h post dose. This may indicate the need for lower doses of INH in female patients. Female sex could be a risk factor for hepatotoxicity, and this may be an explanation for the higher plasma concentrations in women than men at similar INH doses. INH hepatotoxicity may also be unrelated to drug plasma concentrations, being an idiosyncratic mechanism. 22, 23 The distribution of acetylator status in the Iranian population shows a higher prevalence of slow acetylators over rapid acetylators; slow acetylation is a risk factor for hepatotoxicity induced by anti-tuberculosis treatment. 24 However, as we did not determine genotyping, and patients with HIV infection or diabetes mellitus, which are well known determinants of low serum concentrations of anti-tuberculosis drugs, were excluded, it is possible that the most common factors related to exposure to TB drugs were omitted in our study. Furthermore, the fact that we could not determine EMB concentrations is a limitation of our study.
RMP concentrations were not signifi cantly associated with any of the factors studied, and RMP plasma concentrations were outside the therapeutic range in the majority of our patients. According to one study, peak serum concentrations of RMP were more likely to be low in patients with diabetes mellitus (P = 0.03), 15 probably explaining the slower response in these patients. Although patients with diabetes were excluded from our study, RMP plasma values were lower than the target range in almost all patients (92%). In another study, RMP concentrations were substantially outside the target range (low in 47% and high in 2% of patients). 19 Plasma concentrations outside the target ranges should therefore be adjusted accordingly and patients' underlying conditions need to be taken into account.
Although TDM is a recognised tool in the treatment of TB, it is currently under-utilised, and is reserved for patients with more serious illness or nonresponders due to its relatively high cost. 11, 25 TDM performed earlier in the course of treatment may positively affect treatment outcomes such as treatment duration, particularly in slow responders. 15 In this study, we measured 2-h concentrations of anti-tuberculosis drugs to obtain peak serum concentrations, and 6-h concentrations to confi rm the rate and completeness of drug absorption. We did not assess EMB concentrations in our patient population as it is not detectable by a UV detector, which is a limitation of the study. Although EMB is less effective than other fi rst-line drugs, it also has fewer serious adverse effects. 14 According to previous studies, the patient's acetylator status affects INH serum concentrations, and slow acetylation profi le is a risk factor for drug-related hepatotoxicity; 12, 26 it may therefore be necessary to monitor the patient's acetyl-INH: INH ratio at 2 and 6 h post dose.
Improper administration of anti-tuberculosis drugs and poor patient adherence are other reasons for low drug concentrations; however, these factors are less of a concern in a hospital setting, where directly observed therapy is routinely performed. Periodic liver function tests were not performed for many patients, another study limitation. The degradation of antituberculosis drugs in plasma samples (particularly RMP) is another limiting factor in TDM studies. 27 In the current study, 160 drug samples collected from 80 patients were degraded due to inappropriate storage at −20°C. It has been shown that adding ascorbic acid to RMP samples can effectively prevent drug degradation, prolonging RMP stability. 28 Plasma samples should thus be supplemented with ascorbic acid, frozen at −70°C and analysed as soon as possible.
CONCLUSIONS
As low anti-tuberculosis drug concentrations are closely related to drug resistance and therapeutic failure, determinants of drug plasma concentrations should be identifi ed and dose adjustments performed accordingly before starting treatment. Subsequent studies should focus on developing a comprehensive procedure for TDM of anti-tuberculosis drugs and the recruitment of a larger study population to examine the correlation between factors affecting drug plasma concentrations and drug-induced hepatitis.
